Updated hourlyHourly refreshWed, Oct 28, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
NEEDHAM, Mass., Sept. 10, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company’s Board of Directors (Board) effective September 8, 2026.
Sep 10 · 12:05·GlobeNewswire
Finance · Healthcare
DOYLESTOWN, Pa., Sept. 10, 2026 -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Sep 10 · 12:00·GlobeNewswire
Healthcare
Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt
Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt
Sep 10 · 12:00·GlobeNewswire
Healthcare · Food & drink
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.1 This marks the second FDA Priority Review for Enspryng, following the one granted for thyroid eye disease (TED) in June 2026. The FDA is expected to make a decision on approval in MOGAD by 10 January 2027.
Sep 10 · 05:00·GlobeNewswire
Finance · Healthcare
NEW ORLEANS, Sept. 09, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Sep 10 · 02:42·GlobeNewswire
Finance · Healthcare
NEW YORK, Sept. 9, 2026 -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,...
Sep 10 · 00:09·PR Newswire
Finance · Healthcare
WATERTOWN, Mass., Sept. 09, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV). The data, presented in a poster session at the 2026 Society of Hematologic Oncology (SOHO) annual meeting in Houston, TX, demonstrated that treatment with DISC-3405 increased hepcidin and lowered serum iron, translating to reduction in phlebotomy, controlled hematocrit, and improved symptom burden in patients with PV. These data will be featured in an oral presentation at the SOHO conference tomorrow, September 10. Disc also presented an encore of the positive results from the Phase 2 RALLY-MF trial of selcodebart (DISC-0974) in patients with anemia of myelofibrosis (MF) and a new systematic literature review characterizing the humanistic burden of anemia associated with MF through patient reported outcomes.
Sep 9 · 23:25·GlobeNewswire
Healthcare
Procedure reduces stomach size without surgery, giving patients another option for lasting weight loss. BALTIMORE, Sept. 9, 2026 -- For the first time at MedStar Health, patients struggling with obesity who may not want, or may not qualify for traditional bariatric surgery,...
Sep 9 · 21:58·PR Newswire
Healthcare
Vancouver, British Columbia--(September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting").A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the...
Sep 9 · 21:05·Newsfile
Finance · Healthcare
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
Sep 9 · 21:00·GlobeNewswire
Finance · Healthcare
SAN FRANCISCO, Sept. 9, 2026 -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to...
Sep 9 · 20:59·PR Newswire
Healthcare
TORONTO, Sept. 09, 2026 -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition.
Sep 9 · 20:45·GlobeNewswire